SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-21-136977
Filing Date
2021-04-28
Accepted
2021-04-28 16:30:54
Documents
7
Period of Report
2021-06-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A d122680ddef14a.htm DEF 14A 499323
2 GRAPHIC g122680g01a01.jpg GRAPHIC 24667
3 GRAPHIC g122680g10d84.jpg GRAPHIC 171217
4 GRAPHIC g122680g41x39.jpg GRAPHIC 147444
5 GRAPHIC g122680g49p77.jpg GRAPHIC 343797
6 GRAPHIC g122680g67c28.jpg GRAPHIC 204290
7 GRAPHIC g122680g72n39.jpg GRAPHIC 19458
  Complete submission text file 0001193125-21-136977.txt   1726604
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38096 | Film No.: 21864694
SIC: 2834 Pharmaceutical Preparations